KORONER KALP HASTALARINDA CAV1 rs3807990 VARYASYONUNUN LİPİD PROFİLİNDE DİYABETİK KOŞULLARA GÖRE FARKLI ETKİLERİ

Öz

Amaç: Vasküler endotelyumun antiaterojenik fonksiyonunun azalması endotel disfonksiyona sebep olmaktadır. Aterosklerotik sürecin gelişiminde önemli bir mekanizma olan endotel disfonksiyonu nitrik oksit (NO) düzeyinin azalmasıyla karakterizedir. NO miktarı, kendisini üreten eNOS enzim aktivitesinin kaveolin-1 (Cav-1) tarafından inhibisyonuyla düzenlenmektedir. Çalışmamızda diyabetik ve diyabetik-olmayan koroner kalp hastalığında (KKH) CAV1 rs3807990 varyasyonunun metabolik ve lipid biyobelirteçlerin düzeylerine etkisinin ve bu şekilde diyabetik dislipidemiye olası katkısının belirlenmesi amaçlanmıştır. Gereç ve Yöntem: CAV1 geni rs3807990 varyasyonu, 32 diyabetik ve 41 diyabetik-olmayan KKH hastasında Polimeraz Zincir Reaksiyonu-Restriksiyon fragman uzunluğu polimorfizmiyle değerlendirilmiştir. Bulgular: Diyabetik-olmayan KKH grubunda T alleli yüksek total-kolesterol düzeyleriyle ilişkilidir (p=0,021). T alleli taşıyan Diyabetik-KKH hastaları CC-genotiplilere göre yüksek LDL-K (p=0,037) ve glukoz düzeylerine sahip bulundu (p=0,076). Ayrıca diyabetik-KKH hastalarında T alleli serum trigliserid düzeylerinde artışla ilişkili bulunmuştur. Sonuç: Diyabetik-KKH’larda CAV1 rs3807990-T allelinin yüksek glukoz seviyeleriyle ilişkisinin trigliserid seviyelerinde de görülmesi glukoz-trigliserid metabolizması arasındaki ilişkiyle örtüşmektedir. Ayrıca T alleli her iki grupta hiperkolesterolemi ile ilişkili bulunmuştur. Bulgularımız CAV1 rs3807990-T allelinin KKH risk faktörlerinden hiperkolesterolemi gelişiminde etken genetik risk faktörleri arasında yer alabileceği, glukoz düzeylerindeki artışı etkileyebileceği ve bununla ilişkili olarak trigliserid yüksekliğine katkıda bulunabileceği ve sonuç olarak özellikle diyabetik hastalarda dislipidemik fenotipe katkısı olabileceğini önermektedir.

Anahtar Kelimeler

• Kaveolin,CAV1 geni,Dislipidemi,Diyabet,Koroner Kalp Hastalığı

DIFFERENT EFFECTS OF CAV1 rs3807990 VARIATION ON LIPID PROFILE IN PATIENTS WITH CORONARY HEART DISEASE BASED ON PRESENCE OF DIABETES

Öz

Objective: A decreased antiatherogenic function of endothelium causes endothelial dysfunction characterized by decreased nitric oxide (NO) levels. NO amounts can be regulated by the inhibition of eNOS enzyme activity via caveolin-1 (Cav-1). We aimed to determine the effect of CAV1 rs3807990 on metabolic and lipid biomarker levels in diabetic and non-diabetic coronary heart disease (CHD) and to determine the possible contribution to diabetic dyslipidemia. Material and Methods: CAV1 rs3807990 was assessed by the Polymerase Chain Reaction-Restriction Fragment length Polymorphism in 32 diabetics and 41 non-diabetic CHD patients. Results: T allele is associated with high total-cholesterol levels in non-diabetic CHD patients (p=0.021). T-allele carriers in diabetic CHD patients had high LDL-C (p=0.037) and glucose levels (p=0.076) compared to the CC-genotype. In addition, the T allele in diabetic-CHD patients was associated with an increase in serum triglyceride levels. Conclusion: In diabetic-CHDs, the association of CAV1 rs3807990-T allele with high glucose and triglycerides was consistent with the relationship between glucose and triglyceride metabolism. T-allele was also found associated with hypercholesterolemia in both groups. CAV1 rs3807990-T allele may be one of the genetic risk factors for hypercholesterolemia and may cause an increase in glucose. It may also contribute to triglyceride elevation and, consequently, contribute to dyslipidemic phenotype, especially in diabetic-CHD patients.

Anahtar Kelimeler

• Caveolin,CAV1 gene,Dyslipidemia,Diabetes Mellitus,Coronary Heart Disease

Kaynakça

1. 1. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007;3(6):853-76.
2. 2. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem 2007;14(2):2438.
3. 3. Düzgün N, Attilla E. Aterosklerozis ve Sistemik Otoimmün İnflamatuar Hastalıklar. Turkiye Klinikleri J Med Sci 2008;28:508-12.
4. 4. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1(3):183-98.
5. 5. Wang H, Wang AX, Liu Z, Chai W, Barrett EJ. The trafficking/ interaction of eNOS and Caveolin-1 induced by insulin modulates endothelial nitric oxide production. Mol Endocrinol 2009;23(10):1613-23.
6. 6. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004;84:1341-79.
7. 7. Hardin CD, Valloje J. Caveolins in vascular smooth muscle: Form organizing function. Cardiovasc Res 2006;69:808-15.
8. 8. Minetti C, Bado M, Broda P, Sotgia F, Bruno C, Galbiatti F, et al. Impairment of Caveolae Formation and T-System Disorganization in Human Muscular Dystrophy with Caveolin-3 Deficiency. Am J Pathol 2002;160: 265-70.

9. 9. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 2003;23:1161-8.
10. 10. Hnasko R, Lisanti MP. The biology of caveolae:lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003;3:445-64.
11. 11. Sessa WC. Atheroprotection in the absence of ‘caves’: is it the fat, the vessels, or both? Arterioscler Thromb Vasc Biol 2004;24:4-6.
12. 12. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004;5(3):214.
13. 13. Cohen AW, Combs TP, Scherer PE, Lisanti MP. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab 2003;285:E1151-60.
14. 14. Lusis AJ. Atherosclerosis. Nature 2000;407(6801):233-41.
15. 15. Frank PG, Lisanti MP. Caveolin-1 and caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia. Curr Opin Lipidol 2004;15:5239.
16. 16. Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP. Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 2004;43:8312-21.
17. 17. Mora-Garcia G, Ruiz-Diaz M, Gomez-Camargo D, Gomez-Alegria C. Frequency of common polymorphisms in Caveolin 1 (CAV1) gene in adults with high serum triglycerides from Colombian Caribbean Coast. Colombia MéDica 2017;48(4):167-73.
18. 18. Grilo A, Fernandez ML, Beltrán M, Ramirez-Lorca R, González MA, Royo JL, et al. Genetic analysis of CAV1 gene in hypertension and metabolic syndrome. Thromb Haemost 2006;95:696-701.
19. 19. Schwencke C, Braun-Dullaeus RC, Wunderlich C, Strasser RH. Caveolae and caveolin in transmembrane signaling: Implications for human disease. Cardiovasc Res 2006;70:429.
20. 20. Hamilton A, Mittal S, Barnardo MC, Fuggle SV, Friend P, Gough SC, et al. Genetic variation in caveolin-1 correlates with long-term pancreas transplant function. Am J Transplant 2015;15(5):1392-9.
21. 21. Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramírez-Armengol JA, Moreno Nogueira JA, et al. Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep 2006;16:353-9.
22. 22. Pojoga LH, Underwood PC, Goodarzi MO, Williams JS, Adler GK, Jeunemaitre X, et al. Variants of the caveolin-1 gene: a translational investigation linking insulin resistance and hypertension. J Clin Endocrinol Metab 2011;96(8):E1288-92.
23. 23. Teranishi M, Uchida Y, Nishio N, Kato K, Otake H, Yoshida T, et al. Polymorphisms in genes involved in the free-radical process in patients with sudden sensorineural hearing loss and Ménière’s disease. Free Radic Res 2013;47(6-7):498-506.
24. 24. Fang X, Li X, Yin Z, Xia L, Quan X, Zhao Y, et al. Genetic variation at the microRNA binding site of CAV1 gene is associated with lung cancer susceptibility. Oncotarget 2017;8(54):92943-54.
25. 25. Austin ED, Ma L, LeDuc C, Berman Rosenzweig E, Borczuk A, Phillips JA 3rd, et al. Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated with Human Pulmonary Arterial Hypertension. Circ Cardiovasc Genet 2012;5(3):336-43.
26. 26. Bau DT, Chang CH, Tsai RY, Wang HC, Wang RF, Tsai CW, et al. Significant Association of Caveolin-1 Genotypes with Bladder Cancer Susceptibility in Taiwan) Chin J Physiol 2011;54(3):153-60.
27. 27. Chen S, Wang C, Wang X, Xu C, Wu M, Wang P, et al. Significant Association Between CAV1 Variant rs3807989 on 7p31 and Atrial Fibrillation in a Chinese Han Population. J Am Heart Assoc 2015;4(5):e001980.
28. 28. Carey RM, Schoeffel CD, Gildea JJ, Jones JE, McGrath HE, Gordon LN, et al. Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter. Hypertension 2012;60:1359-66.
29. 29. Chen S, Wang X, Wang J, Zhao Y, Wang D, Tan C, et al. Genomic variant in CAV1 increases susceptibility to coronary artery disease and myocardial infarction. Atherosclerosis 2016;246:148-56.
30. 30. Jia W, Qi X, Li Q. Association Between Rs3807989 Polymorphism in Caveolin-1 (CAV1) Gene and Atrial Fibrillation: A Meta-Analysis. Med Sci Monit 2016;22:39616.
31. 31. Vogl-Willis CA, Edwards IJ. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol 2004;24:858-63.
32. 32. Betteridge DJ. Lipid control in patients with diabetes mellitus. Nat Rev Cardiol 2011;8:278-90.
33. 33. Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27:68-71.
34. 34. Ergin E, Akın S, Kazan S, Erdem ME, Tekçe M, Aliustaoğlu M. Lipid Profile of Diabetic Patients: Awareness and the Rate of Treatment Success. SCIE 2013; 24(3):157-63.
35. 35. Muačević-Katanec D, Reiner Ž. Diabetic Dyslipidemia or ‘Diabetes Lipidus? Expert Rev Cardiovasc Ther 2011;9(3):341-8.
36. 36. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:150-9.
37. 37. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, et al. Caveolin-1 deficient mice are lean, resistant to diet-induced obesity, and show hyper-triglyceridemia with adipocyte abnormalities. J Biol Chem 2002;277:8635-47.
38. 38. Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, Lisanti MP. Genetic Ablation of Caveolin-1 Confers Protection Against Atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:98-105.
39. 39. Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, et al. A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. Metabolism 2015;64(12):167481.
40. 40. Yamada Y, Ando F, Shimokata H. Association of gene polymorphisms with blood pressure and the prevalence of hypertension in community-dwelling Japanese individuals. Int J Mol Med 2007;19(4):675-83.
41. 41. Frank PG, Pavlides S, Lisanti MP. Caveolae and transcytosis in endothelial cells: Role in atherosclerosis. Cell Tissue Res 2009;335:41-7.
42. 42. Frank PG, Pavlides S, Cheung MW-C, Daumer K, Lisanti MP. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol 2008;295(1):C242-8.